RenovoRx (RNXT) Cash from Operations (2020 - 2026)
RenovoRx (RNXT) posted Cash from Operations of 3709000.0 for Q1 2026, down 22.81% sequentially from 3020000.0 in Q4 2025, and down 9.7% YoY from 4107477.56 in Q1 2025.
RenovoRx (RNXT) Cash from Operations (2020 - 2026) Analysis & Trends
RenovoRx has reported Cash from Operations for 7 years, with the latest figure at 3709000.0 in Q1 2026.
- Quarterly Cash from Operations fell 9.7% year-over-year to 3709000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11301000.0 (down 9.7% YoY) and the FY2025 annual result came in at 10973000.0, down 20.25% from the prior year.
- Cash from Operations eased to 3709000.0 in Q1 2026 per RNXT's latest filing, from 3020000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1681000.0 in Q4 2022 and troughed at 3709000.0 in Q1 2026.
- A 5-year average of 2522117.65 and a median of 2361000.0 in 2022 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 34.28% in 2022, down 138.78% in 2022.
- Over 5 years, Cash from Operations stood at 1681000.0 in 2022, then retreated by 22.13% to 2053000.0 in 2023, then dropped by 18.36% to 2430000.0 in 2024, then dropped by 24.28% to 3020000.0 in 2025, then dropped by 22.81% to 3709000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3709000.0, 3020000.0, and 2270000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 728.46 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | -2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.87 Mn |
| Jun 30, 2026 | -2.87 Mn |
| Mar 31, 2026 | -3.71 Mn |
| Mar 31, 2026 | -3.71 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Mar 31, 2025 | -3.38 Mn |
| Mar 31, 2025 | -3.38 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.30 Mn |
| Jun 30, 2024 | -2.30 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.20 Mn |